VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Phase 2

Terminated

Conditions: HIV Infections

Interventions: Drug: BMS-955176
Drug: Atazanavir (ATV)
Drug: Ritonavir (RTV)
Drug: Dolutegravir (DTG)
Drug: Tenofovir (TDF)

First Posted Date: 2015-03-11

Last Posted Date: 2018-08-20

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 86

Registration Number: NCT02386098

Locations: 🇹🇭
GSK Investigational Site, Bangkok, Thailand

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: DTG 50 mg
Drug: RPV 25 mg

First Posted Date: 2015-02-27

Last Posted Date: 2016-06-27

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 63

Registration Number: NCT02373930

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

Phase 3

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: BMS-663068
Other: Placebo

First Posted Date: 2015-02-13

Last Posted Date: 2024-07-23

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 371

Registration Number: NCT02362503

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK1265744 30mg

First Posted Date: 2015-02-03

Last Posted Date: 2020-08-05

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT02354950

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: GSK1265744 30 mg

First Posted Date: 2015-02-03

Last Posted Date: 2020-08-28

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT02354937

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Cabotegravir 30 mg current formulation
Drug: Cabotegravir 30 mg micronized new formulation 500 M
Drug: Cabotegravir 30 mg micronized new formulation 650 M
Drug: Cabotegravir 30 mg unmicronized new formulation 500 U
Drug: Cabotegravir 30 mg unmicronized new formulation 650 U

First Posted Date: 2015-01-26

Last Posted Date: 2015-07-13

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 37

Registration Number: NCT02345707

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany

Completed

Conditions: HIV Infections

Interventions: Drug: Dolutegravir/Abacavir/Lamivudin

First Posted Date: 2015-01-21

Last Posted Date: 2019-02-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 403

Registration Number: NCT02342769

Locations: 🇩🇪
GSK Investigational Site, Weimar, Germany

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-663068
Drug: Darunavir
Drug: Cobicistat

First Posted Date: 2014-10-29

Last Posted Date: 2018-01-24

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 32

Registration Number: NCT02277600

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

Food Effect Study With BMS-955176

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-955176

First Posted Date: 2014-10-24

Last Posted Date: 2017-04-17

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 12

Registration Number: NCT02273947

Locations: 🇬🇧
GSK Investigational Site, Ruddington Fields, Nottinghamshire, United Kingdom

Study on Pharmacokinetics

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Rosuvastatin
Drug: BMS-663068

First Posted Date: 2014-09-09

Last Posted Date: 2018-04-17

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 50

Registration Number: NCT02234882

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy